Proteomics is the large-scale study of proteins, their structures, functions, and interactions which are essential to understanding disease mechanisms and developing targeted treatments. It plays a critical role in biomarker discovery, drug development, and personalized medicine. It is driven by advances in mass spectrometry and next-gene sequencing. Proteomics is vital for early diagnosis, chronic disease management, and the future of precision healthcare.
According to BIS Research, global proteomics market is projected to reach $109.71 billion by 2034 up from $33.92 billion in 2024, growing at a CAGR of 12.46%.
Key Drivers:
• Early Diagnosis Demand: High demand for mass spectrometry and bioinformatics tools fuels R&D investments.
• Personalized Medicine Growth: Proteomics helps stratify patients, monitor treatments, and identify disease-specific biomarkers.
• Drug Discovery Support: Aids in target validation and mechanism-of-action studies, streamlining the biopharma R&D pipeline.
Key Challenges:
• Talent Shortage: Lack of skilled professionals limits the adoption and scalability of proteomics technologies.
• Data Complexity: Multidimensional datasets require advanced analytics, standardization, and high infrastructure costs, slowing progress.
Jul 2024 – Thermo Fisher: Acquired Olink Holding for $3.1B, expanding its next-gen proteomics portfolio within Life Sciences Solutions.
Oct 2024 – SCIEX (Danaher): Launched ZenoTOF 7600+ and announced 3 collaborations to advance proteomics system compatibility and performance.
Nov 2024 – Seer & Thermo Fisher: Entered co-marketing agreement to promote integrated proteomics solutions using Seer’s Proteograph and Thermo’s Orbitrap Astral MS.
Nov 2024 – Standard BioTools: Acquired Sengenics and added KREX precision antibody profiling to enhance the SomaScan suite for biomarker research.
By Offering:
Product
Service
By Application:
Drug Discovery
Clinical Diagnostics
and Others
By End User:
Biopharmaceutical Companies
Academic and Research Institutions
Hospitals and Diagnostic Laboratories
and Others
By Region:
North America
Europe
Asia-Pacific
Latin America
and Middle East and Africa
Explore the Full TOC and Download Report Sample >>
The global proteomics market is rapidly expanding, driven by technological advancements, rising healthcare investments, and the growing demand for personalized medicine. Innovations in mass spectrometry, protein microarrays, and next-generation sequencing enhance accuracy and adoption in both research and clinical settings. As emerging markets boost healthcare infrastructure and personalized treatments gain traction, biotech and pharmaceutical companies have significant opportunities to innovate and lead through strategic partnerships.
-BIS Research Analyst Team
The proteomics market is expected to grow at a CAGR of 12.46% from 2024–2034.
Leading companies include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, Bio-Rad Laboratories, Illumina, and others.
Mass spectrometry, protein microarrays, and next-generation sequencing (NGS) are the most widely adopted technologies driving growth and innovation in proteomics.
BIS Research offers KOL-based insights, rigorous segmentation, and strategic advisory across software, hardware, and sensing tech domains.
